Pharmacogenetics of novel glucose-lowering drugs.
Dipeptidyl peptidase-4 inhibitors
Glucagon-like peptide-1 receptor agonists
Pharmacogenetics
Precision medicine
Review
Sodium–glucose cotransporter 2 inhibitors
Type 2 diabetes
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
01
09
2020
accepted:
10
12
2020
pubmed:
18
2
2021
medline:
23
2
2022
entrez:
17
2
2021
Statut:
ppublish
Résumé
The aim of this work was to review studies in which genetic variants were assessed with respect to metabolic response to treatment with novel glucose-lowering drugs: dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i). In total, 22 studies were retrieved from the literature (MEDLINE). Variants of the GLP-1 receptor gene (GLP1R) were associated with a smaller reduction in HbA
Identifiants
pubmed: 33594477
doi: 10.1007/s00125-021-05402-w
pii: 10.1007/s00125-021-05402-w
pmc: PMC8099830
doi:
Substances chimiques
Blood Glucose
0
Dipeptidyl-Peptidase IV Inhibitors
0
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1201-1212Références
Pearson ER (2019) Diabetes: Is there a future for pharmacogenomics guided treatment? Clin Pharmacol Ther 106(2):329–337. https://doi.org/10.1002/cpt.1484
doi: 10.1002/cpt.1484
pubmed: 31012484
pmcid: 6771467
Zhou K, Yee SW, Seiser EL et al (2016) Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet 48(9):1055–1059. https://doi.org/10.1038/ng.3632
doi: 10.1038/ng.3632
pubmed: 27500523
pmcid: 5007158
Rathmann W, Strassburger K, Bongaerts B et al (2019) A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 diabetes. Diabetologia 62(2):286–291. https://doi.org/10.1007/s00125-018-4759-z
doi: 10.1007/s00125-018-4759-z
pubmed: 30413829
Nasykhova YA, Tonyan ZN, Mikhailova AA, Danilova MM, Glotov AS (2020) Pharmacogenetics of type 2 diabetes - progress and prospects. Int J Mol Sci 21(18):6842. https://doi.org/10.3390/ijms21186842
doi: 10.3390/ijms21186842
pmcid: 7555942
Heo CU, Choi CI (2019) Current progress in pharmacogenetics of second-Line antidiabetic medications: Towards precision medicine for type 2 diabetes. J Clin Med 8(3):393. https://doi.org/10.3390/jcm8030393
Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17(6):819–837. https://doi.org/10.1016/j.cmet.2013.04.008
doi: 10.1016/j.cmet.2013.04.008
pubmed: 23684623
pmcid: 23684623
Thomas MC, Cherney DZI (2018) The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61(10):2098–2107. https://doi.org/10.1007/s00125-018-4669-0
doi: 10.1007/s00125-018-4669-0
pubmed: 30132034
Holstein A, Beil W, Kovacs P (2012) CYP2C metabolism of oral antidiabetic drugs-impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug Metab Toxicol 8(12):1549–1563. https://doi.org/10.1517/17425255.2012.722619
doi: 10.1517/17425255.2012.722619
pubmed: 23153186
McCarthy MI (2017) Painting a new picture of personalised medicine for diabetes. Diabetologia 60(5):793–799. https://doi.org/10.1007/s00125-017-4210-x
doi: 10.1007/s00125-017-4210-x
pubmed: 28175964
pmcid: 6518376
Ahlqvist E, Storm P, Käräjämäki A et al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6(5):361–369. https://doi.org/10.1016/S2213-8587(18)30051-2
doi: 10.1016/S2213-8587(18)30051-2
Zaharia OP, Strassburger K, Strom A et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 7(9):684–694. https://doi.org/10.1016/S2213-8587(19)30187-1
doi: 10.1016/S2213-8587(19)30187-1
pubmed: 31345776
Ferreira JP, Duarte K, McMurray JJV et al (2018) Data-driven approach to identify subgroups of heart failure with reduced ejection fraction patients with different prognoses and aldosterone antagonist response patterns. Circ Heart Fail 11(7):e004926. https://doi.org/10.1161/CIRCHEARTFAILURE.118.004926
doi: 10.1161/CIRCHEARTFAILURE.118.004926
pubmed: 29997240
Meloni AR, DeYoung MB, Lowe C et al (2013) GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab 15(1):15–27. https://doi.org/10.1111/j.1463-1326.2012.01663.x
doi: 10.1111/j.1463-1326.2012.01663.x
pubmed: 22776039
Urgeova A, Javorsky M, Klimcakova L et al (2020) Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors. Pharmacogenomics 21(5):317–323. https://doi.org/10.2217/pgs-2019-0147
doi: 10.2217/pgs-2019-0147
pubmed: 32308134
Javorský M, Gotthardová I, Klimčáková L et al (2016) A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins. Diabetes Obes Metab 18(9):941–944. https://doi.org/10.1111/dom.12682
doi: 10.1111/dom.12682
pubmed: 27160388
Han E, Park HS, Kwon O et al (2016) A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes. Medicine 95(44):e5155. https://doi.org/10.1097/MD.0000000000005155
doi: 10.1097/MD.0000000000005155
pubmed: 27858848
pmcid: 5591096
van Vliet-Ostaptchouk JV, van Haeften TW, Landman GW et al (2012) Common variants in the type 2 diabetes KCNQ1 gene are associated with impairments in insulin secretion during hyperglycaemic glucose clamp. PLoS One 7(3):e32148. https://doi.org/10.1371/journal.pone.0032148
doi: 10.1371/journal.pone.0032148
pubmed: 22403629
pmcid: 3293880
Gotthardová I, Javorský M, Klimčáková L et al (2017) KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors. Diabetes Res Clin Pract 130:142–147. https://doi.org/10.1016/j.diabres.2017.05.018
doi: 10.1016/j.diabres.2017.05.018
pubmed: 28624668
Haghvirdizadeh P, Mohamed Z, Abdullah NA, Haghvirdizadeh P, Haerian MS, Haerian BS (2015) KCNJ11: Genetic polymorphisms and risk of diabetes mellitus. J Diabetes Res 2015:908152. https://doi.org/10.1155/2015/908152
doi: 10.1155/2015/908152
pubmed: 26448950
pmcid: 4584059
Jamaluddin JL, Huri HZ, Vethakkan SR (2016) Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. Pharmacogenomics 17(8):867–881. https://doi.org/10.2217/pgs-2016-0010
doi: 10.2217/pgs-2016-0010
pubmed: 27249660
't Hart LM, Fritsche A, Nijpels G et al (2013) The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes 62(9):3275–3281. https://doi.org/10.2337/db13-0227
Ferdaoussi M, Bergeron V, Zarrouki B et al (2012) G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia 55(10):2682–2692. https://doi.org/10.1007/s00125-012-2650-x
doi: 10.1007/s00125-012-2650-x
pubmed: 22820510
pmcid: 3543464
Liao WL, Lee WJ, Chen CC et al (2017) Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes. Oncotarget 8(11):18050–18058. https://doi.org/10.18632/oncotarget.14951
doi: 10.18632/oncotarget.14951
pubmed: 28160554
pmcid: 5392306
Osada UN, Sunagawa H, Terauchi Y et al (2016) A common susceptibility gene for type 2 diabetes is associated with drug response to a DPP-4 Inhibitor: Pharmacogenomic Cohort in Okinawa Japan. PLoS One 11(5):e0154821. https://doi.org/10.1371/journal.pone.0154821
doi: 10.1371/journal.pone.0154821
pubmed: 27139004
pmcid: 4854407
Ubeda M, Rukstalis JM, Habener JF (2006) Inhibition of cyclin-dependent kinase 5 activity protects pancreatic beta cells from glucotoxicity. J Biol Chem 281(39):28858–28864. https://doi.org/10.1074/jbc.M604690200
doi: 10.1074/jbc.M604690200
pubmed: 16887799
Ellingsgaard H, Hauselmann I, Schuler B et al (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17(11):1481–1489. https://doi.org/10.1038/nm.2513
doi: 10.1038/nm.2513
pubmed: 22037645
pmcid: 4286294
Matsui M, Takahashi Y, Takebe N et al (2015) Response to the dipeptidyl peptidase-4 inhibitors in Japanese patients with type 2 diabetes might be associated with a diplotype of two single nucleotide polymorphisms on the interleukin-6 promoter region under a certain level of physical activity. J Diabetes Investig 6(2):173–181. https://doi.org/10.1111/jdi.12260
doi: 10.1111/jdi.12260
pubmed: 25802725
Grant SFA (2019) The TCF7L2 locus: a genetic window into the pathogenesis of type 1 and type 2 Diabetes. Diabetes Care 42(9):1624–1629. https://doi.org/10.2337/dci19-0001
doi: 10.2337/dci19-0001
pubmed: 31409726
pmcid: 6702598
Schäfer SA, Tschritter O, Machicao F et al (2007) Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 50(12):2443–2450. https://doi.org/10.1007/s00125-007-0753-6
doi: 10.1007/s00125-007-0753-6
pubmed: 17661009
pmcid: 2063563
Zimdahl H, Ittrich C, Graefe-Mody U et al (2014) Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia 57(9):1869–1875. https://doi.org/10.1007/s00125-014-3276-y
doi: 10.1007/s00125-014-3276-y
pubmed: 24906949
pmcid: 4119242
Jamaluddin JL, Huri HZ, Vethakkan SR, Mustafa N (2014) Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in type 2 diabetes. Pharmacogenomics 15(2):235–249. https://doi.org/10.2217/pgs.13.234
doi: 10.2217/pgs.13.234
pubmed: 24444412
Wilson JR, Shuey MM, Brown NJ, Devin JK (2017) Hypertension and type 2 diabetes are associated with decreased inhibition of dipeptidyl peptidase-4 by sitagliptin. J Endocr Soc 1(9):1168–1178. https://doi.org/10.1210/js.2017-00312
doi: 10.1210/js.2017-00312
pubmed: 29264572
pmcid: 5686657
Romeo S, Kozlitina J, Xing C et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40(12):1461–1465. https://doi.org/10.1038/ng.257
doi: 10.1038/ng.257
pubmed: 18820647
pmcid: 2597056
Kan H, Hyogo H, Ochi H et al (2016) Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res 46(3):E146–E153. https://doi.org/10.1111/hepr.12552
doi: 10.1111/hepr.12552
pubmed: 26147768
Lin CH, Lee YS, Huang YY, Hsieh SH, Chen ZS, Tsai CN (2015) Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes. J Diabetes Res 2015:176949. https://doi.org/10.1155/2015/176949
doi: 10.1155/2015/176949
pubmed: 25785276
pmcid: 4345081
de Luis DA, Diaz Soto G, Izaola O, Romero E (2015) Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor. J Diabetes Complicat 29(4):595–598. https://doi.org/10.1016/j.jdiacomp.2015.02.010
doi: 10.1016/j.jdiacomp.2015.02.010
Yu M, Wang K, Liu H, Cao R (2019) GLP1R variant is associated with response to exenatide in overweight Chinese Type 2 diabetes patients. Pharmacogenomics 20(4):273–277. https://doi.org/10.2217/pgs-2018-0159
Kirkham TC (2005) Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 16(5–6):297–313. https://doi.org/10.1097/00008877-200509000-00004
doi: 10.1097/00008877-200509000-00004
pubmed: 16148436
de Luis DA, Ovalle HF, Soto GD, Izaola O, de la Fuente B, Romero E (2014) Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2. J Investig Med 62(2):324–327. https://doi.org/10.2310/JIM.0000000000000032
doi: 10.2310/JIM.0000000000000032
pubmed: 24322329
Ferreira MC, da Silva MER, Fukui RT, do Carmo Arruda-Marques M, Azhar S, Dos Santos RF (2019) Effect of TCF7L2 polymorphism on pancreatic hormones after exenatide in type 2 diabetes. Diabetol Metab Syndr 11:10. https://doi.org/10.1186/s13098-019-0401-6
doi: 10.1186/s13098-019-0401-6
pubmed: 30700996
pmcid: 6347826
Goodarzi MO, Lehman DM, Taylor KD et al (2007) SORCS1: a novel human type 2 diabetes susceptibility gene suggested by the mouse. Diabetes 56(7):1922–1929. https://doi.org/10.2337/db06-1677
doi: 10.2337/db06-1677
pubmed: 17426289
Lane RF, Raines SM, Steele JW et al (2010) Diabetes-associated SorCS1 regulates Alzheimer’s amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex. J Neurosci 30(39):13110–13115. https://doi.org/10.1523/JNEUROSCI.3872-10.2010
doi: 10.1523/JNEUROSCI.3872-10.2010
pubmed: 20881129
pmcid: 3274732
Zhou LM, Xu W, Yan XM, Li MXY, Liang H, Weng JP (2017) Association between SORCS1 rs1416406 and therapeutic effect of exenatide. Zhonghua Yi Xue Za Zhi 97(18):1415–1419. [Article in Chinese]. https://doi.org/10.3760/cma.j.issn.0376-2491.2017.18.013
doi: 10.3760/cma.j.issn.0376-2491.2017.18.013
pubmed: 28535629
Zimdahl H, Haupt A, Brendel M et al (2017) Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes. Pharmacogenet Genomics 27(4):135–142. https://doi.org/10.1097/FPC.0000000000000268
doi: 10.1097/FPC.0000000000000268
pubmed: 28134748
Mitsche MA, Hobbs HH, Cohen JC (2018) Patatin-like phospholipase domain–containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. J Biol Chem 293(18):6958–6968. https://doi.org/10.1074/jbc.RA118.002333
doi: 10.1074/jbc.RA118.002333
pubmed: 29555681
pmcid: 5936833
Eriksson JW, Lundkvist P, Jansson PA et al (2018) Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 61(9):1923–1934. https://doi.org/10.1007/s00125-018-4675-2
doi: 10.1007/s00125-018-4675-2
pubmed: 29971527
pmcid: 6096619
Hoeben E, De Winter W, Neyens M, Devineni D, Vermeulen A, Dunne A (2016) Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus. Clin Pharmacokinet 55(2):209–223. https://doi.org/10.1007/s40262-015-0307-x
doi: 10.1007/s40262-015-0307-x
pubmed: 26293616
Francke S, Mamidi RN, Solanki B et al (2015) In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol 55(9):1061–1072. https://doi.org/10.1002/jcph.506
doi: 10.1002/jcph.506
pubmed: 25827774
GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2, Zhou K et al (2011) Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 43(2):117–120. https://doi.org/10.1038/ng.735
doi: 10.1038/ng.735
Tuteja S, Ferguson JF (2019) Gut microbiome and response to cardiovascular drugs. Circ Genom Precis Med 12(9):421–429. https://doi.org/10.1161/CIRCGEN.119.002314
doi: 10.1161/CIRCGEN.119.002314
pubmed: 31462078
pmcid: 6751004
Jones AG, McDonald TJ, Shields BM et al (2016) Markers of β-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care 39(2):250–257. https://doi.org/10.2337/dc15-0258
doi: 10.2337/dc15-0258
pubmed: 26242184
Dennis JM, Shields BM, Hill AV et al (2018) Precision medicine in type 2 diabetes: clinical markers of insulin resistance are associated with altered short- and long-term glycemic response to DPP-4 inhibitor therapy. Diabetes Care 41(4):705–712. https://doi.org/10.2337/dc17-1827
doi: 10.2337/dc17-1827
pubmed: 29386249
pmcid: 6591121
Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT (2003) Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362(9392):1275–1281. https://doi.org/10.1016/S0140-6736(03)14571-0
doi: 10.1016/S0140-6736(03)14571-0
pubmed: 14575972
Pearson ER, Flechtner I, Njølstad PR et al (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355(5):467–477. https://doi.org/10.1056/NEJMoa061759
doi: 10.1056/NEJMoa061759
pubmed: 16885550
Chung WK, Erion K, Florez JC et al (2020) Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63(9):1671–1693. https://doi.org/10.1007/s00125-020-05181-w
doi: 10.1007/s00125-020-05181-w
pubmed: 32556613